

# Xavier Leleu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7095876/publications.pdf>

Version: 2024-02-01

95  
papers

13,433  
citations

53794

45  
h-index

40979

93  
g-index

96  
all docs

96  
docs citations

96  
times ranked

9273  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. <i>Haematologica</i> , 2023, 108, 890-897.	3.5	65
2	Smoldering multiple myeloma: biology, clinical manifestations and management. <i>Leukemia and Lymphoma</i> , 2022, 63, 518-529.	1.3	2
3	Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study. <i>British Journal of Haematology</i> , 2022, 196, 639-648.	2.5	7
4	Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma. <i>Leukemia</i> , 2022, 36, 881-884.	7.2	1
5	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 65-76.	10.7	80
6	Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase II 2 trial. <i>Blood Cancer Journal</i> , 2022, 12, 9.	6.2	14
7	Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. <i>Lancet Haematology</i> , the, 2022, 9, e98-e110.	4.6	32
8	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2022, 23, 416-427.	10.7	54
9	Efficacy and tolerability of <scp>onceâ€‘weekly</scp> selinexor, bortezomib, and dexamethasone in comparison with standard <scp>twiceâ€‘weekly</scp> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <scp>BOSTON</scp> study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
10	Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1859-1867.	3.8	5
11	del(17p) without <i>TP53</i> mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma. <i>Blood</i> , 2021, 137, 1192-1195.	1.4	48
12	Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2021, 39, 757-767.	1.6	98
13	Efficacy and safety of weekly carfilzomib (70â€‘mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 358-367.	1.3	13
14	Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2021, 35, 31-44.	7.2	79
15	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
16	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	10.7	136
17	Effect of age and frailty on the efficacy and tolerability of onceâ€‘weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
18	A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. <i>Blood Cancer Journal</i> , 2021, 11, 89.	6.2	49

#	ARTICLE	IF	CITATIONS
19	Improved survival in multiple myeloma during the 2005–2009 and 2010–2014 periods. <i>Leukemia</i> , 2021, 35, 3600-3603.	7.2	11
20	Waldenström macroglobulinemia and relationship to immune deficiency. <i>Leukemia and Lymphoma</i> , 2021, 62, 2665-2670.	1.3	1
21	Health-related quality of life outcomes from the CANDOR study in patients with relapsed or refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 3002-3010.	1.3	6
22	A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twice-weekly. <i>Expert Review of Hematology</i> , 2021, 14, 1049-1058.	2.2	1
23	Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. <i>Cancers</i> , 2021, 13, 5154.	3.7	30
24	Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article. <i>Cancers</i> , 2021, 13, 5210.	3.7	6
25	A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. <i>Leukemia</i> , 2020, 34, 224-233.	7.2	122
26	Predicting the risk of venous thromboembolism in newly diagnosed myeloma with immunomodulatory drugs: External validation of the IMPEDE VTE score. <i>American Journal of Hematology</i> , 2020, 95, E18-E20.	4.1	11
27	Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 4030-4041.	1.6	56
28	Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. <i>Cancers</i> , 2020, 12, 2885.	3.7	23
29	International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). <i>Blood Cancer Journal</i> , 2020, 10, 102.	6.2	126
30	Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. <i>Lancet</i> , The, 2020, 396, 186-197.	13.7	299
31	Melflufen for relapsed and refractory multiple myeloma. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 1069-1078.	4.1	17
32	Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients. <i>Journal of Clinical Medicine</i> , 2020, 9, 3554.	2.4	4
33	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	13.7	188
34	Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk. <i>Haematologica</i> , 2020, 105, e480-483.	3.5	42
35	Longitudinal clonal architecture of acute myeloid leukemia with NPM1 driver insertion, early TET2 mutations and secondary e6a2 BCR-ABL1 rearrangement. <i>Leukemia and Lymphoma</i> , 2020, 61, 1709-1713.	1.3	0
36	Cost and efficacy of peripheral stem cell mobilization strategies in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 2254-2260.	2.4	5

#	ARTICLE	IF	CITATIONS
37	Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Results of the Phase 3 Candor Study. <i>Blood</i> , 2020, 136, 26-27.	1.4	13
38	Propensity score matching analysis to evaluate the comparative effectiveness of daratumumab versus real-world standard of care therapies for patients with heavily pretreated and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2019, 60, 163-171.	1.3	11
39	Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 2096-2107.	13.7	435
40	Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. <i>New England Journal of Medicine</i> , 2019, 380, 2104-2115.	27.0	684
41	Response to pneumococcal vaccination in multiple myeloma. <i>Cancer Medicine</i> , 2019, 8, 3822-3830.	2.8	20
42	Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2019, 394, 29-38.	13.7	665
43	Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4224-4230.	7.0	12
44	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 781-794.	10.7	254
45	Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. <i>American Journal of Hematology</i> , 2019, 94, 635-640.	4.1	43
46	Activity of Melflufen in RR MM Patients with Extramedullary Disease in the Phase 2 HORIZON Study (OP-106): Promising Results in a High-Risk Population. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e352-e353.	0.4	2
47	Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 9-22.	0.4	21
48	Carfilzomib weekly 20/56 mg/m <sup>2</sup> , lenalidomide and dexamethasone for early relapsed refractory multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, E17-E20.	4.1	5
49	Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. <i>Annals of Hematology</i> , 2018, 97, 831-837.	1.8	0
50	Incidence of neutropenia and use of granulocyte colony-stimulating factors in multiple myeloma: is current clinical practice adequate?. <i>Annals of Hematology</i> , 2018, 97, 387-400.	1.8	21
51	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. <i>Leukemia</i> , 2018, 32, 1542-1560.	7.2	68
52	Heavy+light chain analysis to assign myeloma response is analogous to the IMWG response criteria. <i>Leukemia and Lymphoma</i> , 2018, 59, 583-589.	1.3	3
53	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	1.4	216
54	Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2018, 379, 1811-1822.	27.0	413

#	ARTICLE	IF	CITATIONS
55	Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow. <i>Blood Advances</i> , 2018, 2, 2811-2813.	5.2	69
56	Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. <i>Blood</i> , 2018, 132, 2456-2464.	1.4	301
57	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia. <i>Hematology/Oncology Clinics of North America</i> , 2018, 32, 753-763.	2.2	5
58	Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib+lenalidomide+dexamethasone versus placebo+lenalidomide+dexamethasone in relapsed/refractory multiple myeloma. <i>American Journal of Hematology</i> , 2018, 93, 985-993.	4.1	41
59	Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. <i>New England Journal of Medicine</i> , 2017, 376, 1311-1320.	27.0	924
60	BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. <i>Blood</i> , 2017, 129, 456-459.	1.4	62
61	<i>TP53</i> Mutation and Its Prognostic Significance in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2017, 23, 6325-6335.	7.0	64
62	Usual risk factors do not predict venous thromboembolism in newly diagnosed myeloma treated with immunomodulatory drugs. <i>American Journal of Hematology</i> , 2016, 91, E455-6.	4.1	3
63	IgM <sup>®</sup> and IgM <sup>®</sup> Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia. <i>Clinical Cancer Research</i> , 2016, 22, 5152-5158.	7.0	9
64	Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. <i>American Journal of Hematology</i> , 2016, 91, 575-580.	4.1	83
65	Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. <i>Journal of Clinical Oncology</i> , 2016, 34, 2125-2132.	1.6	91
66	Treatment of Newly Diagnosed Elderly Multiple Myeloma. <i>Cancer Treatment and Research</i> , 2016, 169, 123-143.	0.5	9
67	Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 3609-3617.	1.6	71
68	An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide+dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM). <i>American Journal of Hematology</i> , 2016, 91, 806-811.	4.1	9
69	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	1.3	30
70	Genomic Landscape of <i>CXCR4</i> Mutations in Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2016, 22, 1480-1488.	7.0	102
71	Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results. <i>Blood</i> , 2015, 125, 1411-1417.	1.4	91
72	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma. <i>Blood</i> , 2015, 125, 3100-3104.	1.4	47

#	ARTICLE	IF	CITATIONS
73	Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma: the IFM experience. <i>Blood</i> , 2015, 125, 2095-2100.	1.4	82
74	Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial. <i>Haematologica</i> , 2015, 100, e56-e59.	3.5	34
75	Outcomes after Initial Relapse of Multiple Myeloma: An International Myeloma Working Group Study. <i>Blood</i> , 2015, 126, 4201-4201.	1.4	3
76	IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. <i>Cancer</i> , 2014, 120, 3952-3957.	4.1	29
77	MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. <i>British Journal of Haematology</i> , 2014, 167, 506-513.	2.5	71
78	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	10.7	3,343
79	Front-Line Transplantation Program With Lenalidomide, Bortezomib, and Dexamethasone Combination As Induction and Consolidation Followed by Lenalidomide Maintenance in Patients With Multiple Myeloma: A Phase II Study by the Intergroupe Francophone du Myelome. <i>Journal of Clinical Oncology</i> , 2014, 32, 2712-2717.	1.6	243
80	Combination of International Scoring System 3, High Lactate Dehydrogenase, and t(4;14) and/or del(17p) Identifies Patients With Multiple Myeloma (MM) Treated With Front-Line Autologous Stem-Cell Transplantation at High Risk of Early MM Progression-Related Death. <i>Journal of Clinical Oncology</i> , 2014, 32, 2173-2180.	1.6	150
81	Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients. <i>Haematologica</i> , 2014, 99, 1236-1238.	3.5	35
82	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , 2014, 124, 1404-1411.	1.4	138
83	Comparison of Waldenstrom Macroglobulinemia Responses Using Immunoglobulin Heavy / Light Chain Analysis and Conventional Electrophoresis Techniques. <i>Blood</i> , 2014, 124, 2978-2978.	1.4	1
84	Memory loss during lenalidomide treatment: a report on two cases. <i>BMC Pharmacology &amp; Toxicology</i> , 2013, 14, 41.	2.4	19
85	Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma. <i>Cancer</i> , 2013, 119, 3680-3686.	4.1	30
86	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. <i>British Journal of Haematology</i> , 2013, 160, 171-176.	2.5	226
87	Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02. <i>Blood</i> , 2013, 121, 1968-1975.	1.4	201
88	MYD88 L265P mutation in Waldenstrom macroglobulinemia. <i>Blood</i> , 2013, 121, 4504-4511.	1.4	214
89	MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. <i>Thrombosis and Haemostasis</i> , 2013, 110, 844-851.	3.4	52
90	Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1953-1959.	1.6	273

#	ARTICLE	IF	CITATIONS
91	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
92	Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. <i>Lancet Oncology</i> , The, 2011, 12, 431-440.	10.7	835
93	The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia. <i>Clinical Cancer Research</i> , 2011, 17, 3013-3018.	7.0	46
94	Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. <i>American Journal of Hematology</i> , 2007, 82, 83-84.	4.1	64
95	Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. <i>Experimental Hematology</i> , 2007, 35, 1366-1375.	0.4	61